Brief: Cogent Biosciences Reports Recent Business Highlights And Q1 2023 Financial Results
09/05/2023 13:48
May 9 (Reuters) - Cogent Biosciences Inc COGT.O :
* COGENT BIOSCIENCES REPORTS RECENT BUSINESS HIGHLIGHTS AND
FIRST
QUARTER 2023 FINANCIAL RESULTS
* ENDED 1Q 2023 WITH $220.3 MILLION IN CASH, SUFFICIENT TO
FUND
OPERATIONS INTO 2025
* QTRLY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON
STOCKHOLDERS,
BASIC AND DILUTED $0.54
* Q1 EARNINGS PER SHARE VIEW $-0.57 -- REFINITIV IBES DATA
Source text for Eikon: ID:nGNX3WJRcn
Further company coverage: COGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's